# OCU400 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ocu400

> The FDA approved OCU400, sponsored by Ocugen, Inc. (OCGN), on Aug 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | OCU400 |
| Codes | OCU400 |
| Sponsor | Ocugen, Inc. (OCGN) https://sec-api.dev/companies/ocgn/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | orphan, rmat |

## Timeline

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001628280-24-047846): "In August 2024, we received approval from the FDA to begin our expanded access program (EAP) for the treatment of adult patients, aged 18 or older, with RP." https://www.sec.gov/Archives/edgar/data/1372299/000162828024047846/ocgn-20240930.htm

### 2026: interim data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-11-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-106664): "Intend to release interim data (50% of patients at 8 months of treatment) mid-year 2026." https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-106664): "interim data on 50% of patients at eight months of treatment expected mid-year 2026, and OCU400 (RP) Phase 3 top line data expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-1.htm

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-03-05, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055411): "The Company plans to initiate the rolling BLA submission for OCU400 in the third quarter of 2026 and complete the BLA submission by the second quarter of 2027." https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-023288): "- Completed enrollment in the Phase 3 liMeliGhT clinical trial for OCU400 and are on track to file the rolling BLA in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_ex99-1.htm
- SEC Form 10-K (accession 0001628280-25-010271): "The OCU400 Phase 3 liMeliGhT clinical trial is currently underway, with enrollment on track to meet our target submission of a Biologics License Application ("BLA") and Marketing Authorization Application ("MAA") in mid-2026." https://www.sec.gov/Archives/edgar/data/1372299/000162828025010271/ocgn-20241231.htm
- SEC Form 10-K (accession 0001628280-25-010271): "The OCU400 Phase 3 liMeliGhT clinical trial is currently underway, with enrollment on track to meet our target submission of a BLA and MAA in mid-2026." https://www.sec.gov/Archives/edgar/data/1372299/000162828025010271/ocgn-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-054866): "We expect to begin a rolling BLA submission in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1372299/000110465926054866/tm2613474d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010245): "Actively enrolling patients in the U.S. and Canada in the Phase 3 liMeliGhT clinical trial for the treatment of RP and are on track to complete enrollment in the first half of 2025 and file BLA and MAA submissions in mid-2026." https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/ocgn-20250305xex991.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-11-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-106664): "Intend to initiate BLA rolling submission in the first half of 2026 and release Phase 3 top-line data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-106664): "Intend to initiate BLA rolling submission in the first half of 2026 and release Phase 3 top line data in the fourth quarter of 2026 Recent Accomplishment" https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-2.htm

### Q1 2027: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-07-13, last confirmed 2026-07-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-082897): "3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow." https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/tm2620295d1_ex99-1.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-03-04, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124836): "Ocugen is conducting the Phase 3 liMeliGhT clinical trial of OCU400, with topline data expected in the first quarter of 2027, followed by planned global regulatory submissions, including a Biologics License Application in the U.S." https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/tm2629434d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-115921): "Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical trial with a topline data readout expected in the first quarter of 2027, followed by global regulatory submissions, including a Biologics" https://www.sec.gov/Archives/edgar/data/1372299/000110465926115921/tm2627592d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055411): "Topline Phase 3 data expected in the first quarter of 2027, advancing OCU400 towards potential approval in the fourth quarter of 2027 as a treatment option for early- to late-stage RP." https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-054866): "Topline Phase 3 data expected in the first quarter of 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RP." https://www.sec.gov/Archives/edgar/data/1372299/000110465926054866/tm2613474d1_ex99-1.htm
- SEC Form 10-Q (accession 0001628280-26-054057): "Topline Phase 3 data is expected in the first quarter of 2027, advancing OCU400 towards potential approval in the fourth quarter of 2027 as a treatment option for early- to late stage RP." https://www.sec.gov/Archives/edgar/data/1372299/000162828026054057/ocgn-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-032454): "Topline Phase 3 data is expected in the first quarter of 2027, advancing OCU400 towards potential approval in the fourth quarter of 2027 as a treatment option for early- to late-stage RP." https://www.sec.gov/Archives/edgar/data/1372299/000162828026032454/ocgn-20260331.htm
- SEC Form 10-K (accession 0001628280-26-014435): "Topline Phase 3 data expected in the first quarter of 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RP." https://www.sec.gov/Archives/edgar/data/1372299/000162828026014435/ocgn-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122401): ""As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year."" https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm
- SEC Form 10-Q (accession 0001628280-26-069835): "Topline Phase 3 data is expected in the first quarter of 2027, with plans to submit a biologics license application ("BLA") shortly after." https://www.sec.gov/Archives/edgar/data/1372299/000162828026069835/ocgn-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124836): "Ocugen receives an upfront license fee, potential development and milestone payments totaling up to $7.1 million, including $6.1 million associated with the upfront payment and OCU400 top-line results (expected in the first quarter of 2027), a high single-digit percentage royalty on net sales, and 50% of gross profits from OCU400 net sales across the region" https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/tm2629434d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091691): "Remain on track to announce top-line results for two late-stage clinical programs, OCU400 for RP and OCU410ST for Stargardt disease in 1Q 2027 and 2Q 2027, respectively" https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-082897): "3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow." https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/tm2620295d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ocu400.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OCU400 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ocu400

```bibtex
@misc{secapidev_pdufa_ocu400_20261116,
  title        = {OCU400 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ocu400}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ocu400_20261116","title":"OCU400 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ocu400","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
